Nivolumab clinical trials
Also written Opdivo, BMS-936558 and ONO-4538.
Its developmentBy 8 companies, company by company145 company-led studies, furthest phase 4: when each phase was reached, its deals, target and what is ahead.Includes 3 studies of Nivolumab and Recombinant Human Hyaluronidase.
Related medicines add 2 studies
Counted the way a researcher would: Nivolumab with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
ClinicalTrials.gov finds 2,045 studies for Nivolumab. How that becomes 1,032 hereChecked on ClinicalTrials.gov
Every study that search finds has been read, apart from the 1 newest, to see whether and how it gives Nivolumab. Its counts are asked again every night. How drug pages count
- 2,045Found by its intervention search · See all 2,045 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 1,756 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −17
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic MelanomaNCT01993719 · Earlier treatment, not given in this studyReport a problem
- Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric JunctionNCT02578368 · Not given here; the search matched a related termReport a problem
- An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or OpdivoNCT02763761 · Earlier treatment; the study treats its side effectsReport a problem
- Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With AtezolizumabNCT02919449 · Not given here; the search matched a related termReport a problem
- Biomarker-Integrated Umbrella, Advanced Gastric CancerNCT02951091 · Not given here; the search matched a related termReport a problem
- Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab TreatmentNCT03132675 · Earlier treatment, not given in this studyReport a problem
- Fecal Microbiota Transplant (FMT) in Melanoma PatientsNCT03341143 · Earlier treatment, not given in this studyReport a problem
- Immunomonitoring and Biomarker Research in Patients With Squamous Cell Anal CarcinomaNCT03942900 · Not given here; the search matched a related termReport a problem
- Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint InhibitorsNCT03945773 · Earlier treatment, not given in this studyReport a problem
- Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck CancerNCT03993353 · Not given here; the search matched a related termReport a problem
- Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaNCT04624113 · Earlier treatment, not given in this studyReport a problem
- Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell CarcinomaNCT04714697 · Earlier treatment, not given in this studyReport a problem
- A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)NCT05993234 · Earlier treatment, not given in this studyReport a problem
- TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced Nasopharyngeal CarcinomaNCT06561763 · A slip in the record; nimotuzumab is givenReport a problem
- A Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal CancerNCT06584435 · Named only in the record's backgroundReport a problem
- Omitting Therapeutic Lymph Node Dissection in Patients With Melanoma (Stage 3) and Major Pathological Response in the Index Lymph NodeNCT06754904 · Earlier treatment; the study omits node dissectionReport a problem
- QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric CancerNCT07315035 · Named only in the record's backgroundReport a problem
- 2,028Give Nivolumab to participants
- −229Observe patients on it, or give it outside a trial
- −11Use it as a tool: an imaging tracer or a test of drug response
- −38Compare another treatment with it
- −718Give it beside what is tested
- 1,032Test it: the count on this site
Get an email when these change. Save the Nivolumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 22 Dec 2014 · OPDIVO · BLA 125554 (FDA, Drugs@FDA)
- European Union
- 19 Jun 2015 · Opdivo · EMEA/H/C/003985 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Brand
- Opdivo
- 433
In one entry with another drug
Given together, or one or the other
Biosimilars
- ABP 206
- 2
- BCD-263
- 2
- CMAB819
- 1
Studies by the year they started
1,029 studies that test it; most in 2019 (152); 2 more planned to start later
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 12 |
| 2013 | 10 |
| 2014 | 22 |
| 2015 | 51 |
| 2016 | 82 |
| 2017 | 145 |
| 2018 | 144 |
| 2019 | 152 |
| 2020 | 106 |
| 2021 | 73 |
| 2022 | 60 |
| 2023 | 50 |
| 2024 | 40 |
| 2025 | 37 |
| 2026 | 35 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 167 · Other 865
Bristol-Myers Squibb (128) · National Cancer Institute (NCI) (73) · M.D. Anderson Cancer Center (44) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (27) · Memorial Sloan Kettering Cancer Center (23) · H. Lee Moffitt Cancer Center and Research Institute (19) · The Netherlands Cancer Institute (19) · Dana-Farber Cancer Institute (17)
Often tested with
Tested in the same studies.
Ipilimumab (320) · Pembrolizumab (40) · Cabozantinib (37) · Cisplatin (26) · Relatlimab (25) · Gemcitabine (23) · Paclitaxel (20) · Carboplatin (17)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 20 phase 3 studies under way
Nivolumab is the comparator. A study of two new drugs counts under both.
- 1Volrustomig · AstraZeneca · next primary completion Nov 2028
- 1Durvalumab · AstraZeneca
- 1Tremelimumab · AstraZeneca
- 1Enfortumab vedotin · AstraZeneca
- 1Darovasertib · IDEAYA Biosciences · next primary completion Jan 2027
- 1Zongertinib · Boehringer Ingelheim · next primary completion Feb 2032
- 1Notiretatug rezetecan · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · next primary completion Dec 2031
- 1Adebrelimab · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · next primary completion Dec 2031
New treatments tested with it · 8 most studied
New when their studies opened, with Nivolumab beside them; studies of each.
Reaching primary completion within a year · 118, 9 in phase 3
Studies that test Nivolumab, phase 3 first.
- Dec 2026Identification and Treatment Of Micrometastatic Disease in Stage III Colon CancerPhase 3 · Massachusetts General Hospital
- Mar 2027EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer PatientsPhase 3 · National Cancer Institute (NCI)
- May 2027Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)Phase 3 · National Cancer Institute (NCI)
- Jun 2027Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell LymphomaPhase 3 · National Cancer Institute (NCI)
- Jul 2027Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ AdenocarcinomaPhase 3 · Fudan University
- Aug 2027A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and NeckPhase 3 · Groupe Oncologie Radiotherapie Tete et Cou
- Sep 2027Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk MelanomaPhase 3 · University Hospital, Essen
- Oct 2027Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care ImmunotherapiesPhase 3 · University of Kansas Medical Center
- Oct 2027Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE TrialPhase 2/3 · National Cancer Institute (NCI)
- Nov 2026Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated GlioblastomaPhase 2 · Memorial Sloan Kettering Cancer Center
Studies
Open first, then newest update. How each study uses Nivolumab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 1,032
- Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin LymphomaNot yet recruitingPhase 2/3National Cancer Institute (NCI)NCT07572123With brentuximab vedotin as maintenance in Hodgkin lymphomaWritten as NivolumabHow we knowReport a problem
- Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsRecruitingPhase 2National Cancer Institute (NCI)NCT03866382With ipilimumab and cabozantinib in rare genitourinary tumoursWritten as NivolumabHow we knowReport a problem
- BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyRecruitingPhase 2National Cancer Institute (NCI)NCT05136196With cabozantinib in melanoma and skin cancerWritten as NivolumabHow we knowReport a problem
- Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell LymphomaRecruitingPhase 1National Cancer Institute (NCI)NCT05272384With decitabine and cedazuridine in lymphomaWritten as NivolumabHow we knowReport a problem
- A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)RecruitingPhase 2National Cancer Institute (NCI)NCT06064097With gemcitabine and cisplatin before radiotherapyWritten as NivolumabHow we knowReport a problem
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVORecruitingPhase 1National Cancer Institute (NCI)NCT03816345In cancer patients with autoimmune disordersWritten as NivolumabHow we knowReport a problem
- Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomasRecruitingPhase 2National Cancer Institute (NCI)NCT03258567Alone in EBV-positive lymphoproliferative disordersWritten as NivolumabHow we knowReport a problem
- bNAbs and Anti-PD-1 in HIVRecruitingPhase 2Ole Schmeltz SøgaardNCT07820813Added to broadly neutralising antibodies in HIVWritten as NivolumabHow we knowReport a problem
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabRecruitingPhase 3National Cancer Institute (NCI)NCT05675410With brentuximab vedotin added to ABVD in Hodgkin lymphomaWritten as NivolumabHow we knowReport a problem
- Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE TrialRecruitingPhase 2/3National Cancer Institute (NCI)NCT06203600Added to paclitaxel and ramucirumab in gastric cancerWritten as NivolumabHow we knowReport a problem
- Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IORecruitingPhase 2The Netherlands Cancer InstituteNCT03815890Alone or with new partners before breast surgeryWritten as NivolumabHow we knowReport a problem
- A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 2National Cancer Institute (NCI)NCT04546399Added to blinatumomab in relapsed leukaemiaWritten as NivolumabHow we knowReport a problem
- Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)RecruitingEarly Phase 1Vanderbilt-Ingram Cancer CenterNCT07741565Fluorescently labelled form injected into head and neck tumoursHow we knowReport a problem
- Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell CarcinomaRecruitingPhase 2The First Affiliated Hospital of Guangzhou Medical UniversityNCT05964101With carboplatin and paclitaxel before tracheal cancer surgeryWritten as Nivolumab Injection [Opdivo]How we knowReport a problem
- A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%RecruitingPhase 3Bristol-Myers SquibbNCT06561386With relatlimab and chemotherapy against pembrolizumabWritten as NivolumabHow we knowReport a problem
- Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)RecruitingPhase 2The First Affiliated Hospital of Guangzhou Medical UniversityNCT06926790With ipilimumab before lung surgeryWritten as Nivolumab & IpilimumabHow we knowReport a problem
- Pan Tumor Rollover StudyRecruitingPhase 2Bristol-Myers SquibbNCT03899155Long-term roll-over, alone or in combinationsWritten as NivolumabHow we knowReport a problem
- NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCCNot yet recruitingPhase 2Shanghai Zhongshan HospitalNCT07919717With ipilimumab before repeat surgery for recurrent liver cancerWritten as NivolumabHow we knowReport a problem
- Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin LymphomaRecruitingPhase 1/2Veronika BachanovaNCT03681561With ruxolitinib in Hodgkin lymphomaWritten as NivolumabHow we knowReport a problem
- Hepzato Kit and Opdualag for Metastatic Melanoma and Liver MetastasisRecruitingPhase 1/2University of Wisconsin, MadisonNCT07281924With relatlimab and liver perfusion in melanomaHow we knowReport a problem
See all 1,032 studies that test Nivolumab →
Behind its US label · 29 — the studies the FDA label of OPDIVO describes
From the Clinical Studies section of OPDIVO (2026-08), as openFDA has it. A study the site does not hold is left out.
- An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple MyelomaCompletedPhase 1/2Bristol-Myers SquibbNCT01592370How we knowReport a problem
- Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)CompletedPhase 3Bristol-Myers SquibbNCT01642004How we knowReport a problem
- An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver CancerCompletedPhase 1/2Bristol-Myers SquibbNCT01658878How we knowReport a problem
- Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)CompletedPhase 3Bristol-Myers SquibbNCT01668784How we knowReport a problem
- Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLCCompletedPhase 3Bristol-Myers SquibbNCT01673867How we knowReport a problem
- A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)CompletedPhase 3Bristol-Myers SquibbNCT01721746How we knowReport a problem
- Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic MelanomaCompletedPhase 3Bristol-Myers SquibbNCT01721772How we knowReport a problem
- Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)CompletedPhase 3Bristol-Myers SquibbNCT01844505How we knowReport a problem
- A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadCompletedPhase 2Bristol-Myers SquibbNCT02060188How we knowReport a problem
- Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)CompletedPhase 3Bristol-Myers SquibbNCT02105636How we knowReport a problem
- Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)CompletedPhase 2Bristol-Myers SquibbNCT02181738How we knowReport a problem
- Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)CompletedPhase 3Bristol-Myers SquibbNCT02231749How we knowReport a problem
- A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder CancerCompletedPhase 2Bristol-Myers SquibbNCT02387996How we knowReport a problem
- Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV MelanomaCompletedPhase 3Bristol-Myers SquibbNCT02388906How we knowReport a problem
- An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 3Bristol-Myers SquibbNCT02477826How we knowReport a problem
- Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal CancerCompletedPhase 3Ono Pharmaceutical Co. LtdNCT02569242How we knowReport a problem
- An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the CancerCompletedPhase 3Bristol-Myers SquibbNCT02632409How we knowReport a problem
- An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction CancerCompletedPhase 3Bristol-Myers SquibbNCT02743494How we knowReport a problem
- Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerCompletedPhase 3Bristol-Myers SquibbNCT02872116How we knowReport a problem
- Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma PatientsCompletedPhase 3Bristol-Myers SquibbNCT02899299How we knowReport a problem
- A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 3Bristol-Myers SquibbNCT02998528How we knowReport a problem
- Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial CancerCompletedPhase 3Bristol-Myers SquibbNCT03036098How we knowReport a problem
- A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell CarcinomaCompletedPhase 3Bristol-Myers SquibbNCT03141177How we knowReport a problem
- A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus CisplatinCompletedPhase 3Bristol-Myers SquibbNCT03143153How we knowReport a problem
- A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLCCompletedPhase 3Bristol-Myers SquibbNCT03215706How we knowReport a problem
- Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin LymphomaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT03907488How we knowReport a problem
- A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung CancerActive, not recruitingPhase 3Bristol-Myers SquibbNCT04025879How we knowReport a problem
- A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular CarcinomaCompletedPhase 3Bristol-Myers SquibbNCT04039607How we knowReport a problem
- Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C MelanomaActive, not recruitingPhase 3Bristol-Myers SquibbNCT04099251How we knowReport a problem
Tested on its own · 215 — no other medicine in its arm
- Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomasRecruitingPhase 2National Cancer Institute (NCI)NCT03258567Alone in EBV-positive lymphoproliferative disordersWritten as NivolumabHow we knowReport a problem
- Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell CarcinomaRecruitingPhase 2The First Affiliated Hospital of Guangzhou Medical UniversityNCT05964101With carboplatin and paclitaxel before tracheal cancer surgeryWritten as Nivolumab Injection [Opdivo]How we knowReport a problem
- An Exploratory Study of Single-Dose Neoadjuvant Nivolumab Without Surgical Delay in Patients With Resectable HCCNot yet recruitingPhase 2National Taiwan University HospitalNCT07902258A single dose before liver cancer surgeryWritten as NivolumabHow we knowReport a problem
- Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal CancerRecruitingPhase 2Dr. Te VuongNCT07645118After brachytherapy before rectal surgeryWritten as NivolumabHow we knowReport a problem
- Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based TreatmentRecruitingPhase 2Maria Sklodowska-Curie National Research Institute of OncologyNCT04875611Alone in nasopharyngeal cancerWritten as OpdivoHow we knowReport a problem
- Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) ProgramRecruitingPhase 2Mayo ClinicNCT06265285Subcutaneous at home against in clinicWritten as NivolumabHow we knowReport a problem
- Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO TrialNot yet recruitingPhase 2Fred Hutchinson Cancer CenterNCT07576725Low dose and reduced frequency in advanced cancerWritten as NivolumabHow we knowReport a problem
- Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant LesionsRecruitingPhase 2M.D. Anderson Cancer CenterNCT06561087Intralesional against placebo for oral premalignant lesionsWritten as NivolumabHow we knowReport a problem
- Study to ONO-4538 in Patients With Rhabdoid TumorRecruitingPhase 2Ono Pharmaceutical Co., Ltd.NCT06622941Alone in rhabdoid tumoursWritten as ONO-4538How we knowReport a problem
- Neoadjuvant Lymph Node Targeted Immunotherapy in Cervical Cancer: a Feasibility Study (NEOLYNC)RecruitingPhase 1University Medical Center GroningenNCT07653503Lymph node-targeted before cervical cancer surgeryWritten as NivolumabHow we knowReport a problem
- Evaluation of the Efficacy and Safety of Nivolumab Neoadjuvant Treatment of Patients With Locally Advanced Oral Squamous Cell CarcinomaNot yet recruitingPhase 2Prof. Lars Olaf CardellNCT07514767Before surgery in oral cancerWritten as Nivolumab (240 mg)How we knowReport a problem
- Repositioning Immunotherapy in VetArans With Lung CancerRecruitingPhase 2VA Office of Research and DevelopmentNCT06275360With chemotherapy and radiotherapy in lung cancerWritten as NivolumabHow we knowReport a problem
- ONO-4538 Study in Patients With Richter's TransformationRecruitingPhase 2Ono Pharmaceutical Co., Ltd.NCT06936943Alone in Richter's transformationWritten as ONO-4538How we knowReport a problem
- Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With SarcomaRecruitingPhase 1/2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03465592After half-matched transplant in sarcomaWritten as NivolumabHow we knowReport a problem
- Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic AdenocarcinomaRecruitingPhase 2University of LouisvilleNCT03080974With irreversible electroporation in pancreatic cancerWritten as NivolumabHow we knowReport a problem
- PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin LymphomaRecruitingPhase 2National Research Center for Hematology, RussiaNCT07209059With chemotherapy, PET-adapted, in Hodgkin lymphomaWritten as NivolumabHow we knowReport a problem
- The IMmunotherapy Pleural 5-ALA PDTRecruitingPhase 2University Hospital, LilleNCT04400539With photodynamic therapy in mesotheliomaWritten as Nivolumab InjectionHow we knowReport a problem
- Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell CarcinomaRecruitingPhase 2National Taiwan University HospitalNCT07152678With radiotherapy and brachytherapy in esophageal cancerWritten as Nivolumab (240 mg)How we knowReport a problem
- A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG)RecruitingNot applicableDaniel MorgensternNCT06519682Upfront in children with glioblastomaWritten as NivolumabHow we knowReport a problem
- Recurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of NivolumabRecruitingPhase 2National Cancer Center Hospital EastNCT07100704Alone in olfactory neuroblastomaWritten as NivolumabHow we knowReport a problem
Showing 20 of 215. See all 215 →
Tested with established drugs · 136 — they are given beside it
- bNAbs and Anti-PD-1 in HIVRecruitingPhase 2Ole Schmeltz SøgaardNCT07820813Added to broadly neutralising antibodies in HIVWritten as NivolumabHow we knowReport a problem
- Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE TrialRecruitingPhase 2/3National Cancer Institute (NCI)NCT06203600Added to paclitaxel and ramucirumab in gastric cancerWritten as NivolumabHow we knowReport a problem
- ONO-4538 Phase II Rollover Study (ONO-4538-98)RecruitingPhase 2Ono Pharmaceutical Co., Ltd.NCT04566380Long-term rollover, alone or with partnersWritten as ONO-4538How we knowReport a problem
- Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and RelatlimabRecruitingPhase 2Duke UniversityNCT06816927Alone or with relatlimab around glioblastoma surgeryWritten as NivolumabHow we knowReport a problem
- Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung CancerRecruitingPhase 2Hospital das Clínicas de Ribeirão PretoNCT07084610With chemotherapy before surgery, with metabolic biomarkersWritten as Nivolumab 3 mg/kg + platinum-based chemotherapy (2 cycles, neoadjuvant)How we knowReport a problem
- Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in MelanomaRecruitingEarly Phase 1H. Lee Moffitt Cancer Center and Research InstituteNCT04741997Adjuvant after incomplete response to BRAF-MEK therapyWritten as NivolumabHow we knowReport a problem
- NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain TumorsRecruitingPhase 1Children's National Research InstituteNCT07664176With focused ultrasound in childhood brain tumoursWritten as NivolumabHow we knowReport a problem
- Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHLRecruitingPhase 2M.D. Anderson Cancer CenterNCT07551583With AVD in young patients with Hodgkin lymphomaWritten as NivolumabHow we knowReport a problem
- Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell CarcinomaRecruitingPhase 2Melanoma Institute AustraliaNCT06288191With relatlimab before skin cancer surgeryWritten as Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combinationHow we knowReport a problem
- Neoadjuvant Nivolumab and Relatlimab in Merkel Cell CarcinomaRecruitingPhase 2Melanoma Institute AustraliaNCT06151236With relatlimab before Merkel cell surgeryWritten as Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combinationHow we knowReport a problem
- Low Dose Nivolumab in Adults Living With HIV on Antiretroviral TherapyRecruitingPhase 1/2University of MelbourneNCT05187429Low dose in people living with HIVWritten as Nivolumab 10 MG/ML [Opdivo]How we knowReport a problem
- Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLCRecruitingPhase 3Dr Arvindran A/L AlagaNCT07050043Low dose added to chemotherapy in lung cancerWritten as Nivolumab 40mgHow we knowReport a problem
- Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver TransplantationRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT05475613One anti-PD-1 option in downstaging before liver transplantHow we knowReport a problem
- Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric CancerRecruitingPhase 2Kidney Cancer Research BureauNCT05859477With CAPOX in FGFR2-positive gastric cancerWritten as NivolumabHow we knowReport a problem
- Radiation Free Chemotherapy for Early Hodgkin LymphomaRecruitingPhase 2Medical University of GdanskNCT04866654Radiation-free with chemotherapy in Hodgkin lymphomaWritten as Nivolumab 10 MG/MLHow we knowReport a problem
- Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF MutationActive, not recruitingPhase 2National Cancer Institute (NCI)NCT05308446Added to encorafenib and cetuximab in colorectal cancerWritten as NivolumabHow we knowReport a problem
- EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer PatientsActive, not recruitingPhase 3National Cancer Institute (NCI)NCT04444921Added to carboplatin and paclitaxel in anal cancerWritten as NivolumabHow we knowReport a problem
- Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by SurgeryActive, not recruitingEarly Phase 1M.D. Anderson Cancer CenterNCT02210117Before surgery, alone or with bevacizumab or ipilimumabWritten as NivolumabHow we knowReport a problem
- Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar CancerActive, not recruitingPhase 1/2M.D. Anderson Cancer CenterNCT04380545With fluorouracil and interferon in fibrolamellar cancerWritten as NivolumabHow we knowReport a problem
- Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular CarcinomaActive, not recruitingPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT04658147Alone or with new relatlimab before liver surgeryWritten as NivolumabHow we knowReport a problem
Showing 20 of 136. See all 136 →
Tested in a combination · 681 — another drug in the study is under test too
- Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin LymphomaNot yet recruitingPhase 2/3National Cancer Institute (NCI)NCT07572123With brentuximab vedotin as maintenance in Hodgkin lymphomaWritten as NivolumabHow we knowReport a problem
- Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsRecruitingPhase 2National Cancer Institute (NCI)NCT03866382With ipilimumab and cabozantinib in rare genitourinary tumoursWritten as NivolumabHow we knowReport a problem
- BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyRecruitingPhase 2National Cancer Institute (NCI)NCT05136196With cabozantinib in melanoma and skin cancerWritten as NivolumabHow we knowReport a problem
- Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell LymphomaRecruitingPhase 1National Cancer Institute (NCI)NCT05272384With decitabine and cedazuridine in lymphomaWritten as NivolumabHow we knowReport a problem
- A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)RecruitingPhase 2National Cancer Institute (NCI)NCT06064097With gemcitabine and cisplatin before radiotherapyWritten as NivolumabHow we knowReport a problem
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVORecruitingPhase 1National Cancer Institute (NCI)NCT03816345In cancer patients with autoimmune disordersWritten as NivolumabHow we knowReport a problem
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabRecruitingPhase 3National Cancer Institute (NCI)NCT05675410With brentuximab vedotin added to ABVD in Hodgkin lymphomaWritten as NivolumabHow we knowReport a problem
- Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IORecruitingPhase 2The Netherlands Cancer InstituteNCT03815890Alone or with new partners before breast surgeryWritten as NivolumabHow we knowReport a problem
- A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 2National Cancer Institute (NCI)NCT04546399Added to blinatumomab in relapsed leukaemiaWritten as NivolumabHow we knowReport a problem
- Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)RecruitingEarly Phase 1Vanderbilt-Ingram Cancer CenterNCT07741565Fluorescently labelled form injected into head and neck tumoursHow we knowReport a problem
- A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%RecruitingPhase 3Bristol-Myers SquibbNCT06561386With relatlimab and chemotherapy against pembrolizumabWritten as NivolumabHow we knowReport a problem
- Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)RecruitingPhase 2The First Affiliated Hospital of Guangzhou Medical UniversityNCT06926790With ipilimumab before lung surgeryWritten as Nivolumab & IpilimumabHow we knowReport a problem
- Pan Tumor Rollover StudyRecruitingPhase 2Bristol-Myers SquibbNCT03899155Long-term roll-over, alone or in combinationsWritten as NivolumabHow we knowReport a problem
- NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCCNot yet recruitingPhase 2Shanghai Zhongshan HospitalNCT07919717With ipilimumab before repeat surgery for recurrent liver cancerWritten as NivolumabHow we knowReport a problem
- Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin LymphomaRecruitingPhase 1/2Veronika BachanovaNCT03681561With ruxolitinib in Hodgkin lymphomaWritten as NivolumabHow we knowReport a problem
- Hepzato Kit and Opdualag for Metastatic Melanoma and Liver MetastasisRecruitingPhase 1/2University of Wisconsin, MadisonNCT07281924With relatlimab and liver perfusion in melanomaHow we knowReport a problem
- Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieRecruitingPhase 4IsalaNCT06031233Shortened infusion, one checkpoint optionWritten as NivolumabHow we knowReport a problem
- Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade GliomaEnrolling by invitationPhase 1Andrew P. GrovesNCT06896110Intrathecal with azacitidine in high-grade gliomaWritten as NivolumabHow we knowReport a problem
- MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.RecruitingPhase 2Swiss Cancer InstituteNCT07574047One checkpoint option; infusion time of day is the questionHow we knowReport a problem
- Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular CarcinomaRecruitingPhase 2University of California, IrvineNCT04472767With ipilimumab, cabozantinib and TACE in liver cancerWritten as NivolumabHow we knowReport a problem
Showing 20 of 681. See all 681 →
Beside an established treatment under test · 112 — an approved drug, surgery or radiation is what the study tests
Tested with Nivolumab: Radiation 33 · Surgery or a procedure 30 · Ipilimumab 12 · cabozantinib 9 · Oxaliplatin 5 · relatlimab 4 · Carboplatin 3 · Cisplatin 2
- Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaRecruitingPhase 2National Cancer Institute (NCI)NCT05112601In every armBoth arms take it; ipilimumab is addedWritten as NivolumabHow we knowReport a problem
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal CancerRecruitingPhase 2National Cancer Institute (NCI)NCT06029270In every armBoth arms take it; relatlimab is addedWritten as NivolumabHow we knowReport a problem
- PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver CancerRecruitingPhase 2Samsung Medical CenterNCT07884877One systemic option; PULSAR radiotherapy is testedHow we knowReport a problem
- Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN StudyRecruitingPhase 2/3National Cancer Institute (NCI)NCT05987241In every armBoth arms take it; relatlimab is added by ctDNAWritten as NivolumabHow we knowReport a problem
- First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.RecruitingPhase 3Gustave Roussy, Cancer Campus, Grand ParisNCT06840782One systemic alternative; local ablative treatment is addedHow we knowReport a problem
- Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)RecruitingPhase 2AHS Cancer Control AlbertaNCT05663775Every patient takes it with ipilimumab; mesalamine is testedHow we knowReport a problem
- Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant AscitesRecruitingPhase 1/2Asan Medical CenterNCT07149090Every patient takes it with chemotherapy; lenvatinib is testedHow we knowReport a problem
- mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric AdenocarcinomaRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT05677490In every armBoth arms take it; mFOLFIRINOX against mFOLFOXWritten as NivolumabHow we knowReport a problem
- Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI TrialRecruitingPhase 2NRG OncologyNCT05327686In every armOne standard option; SABR is addedWritten as NivolumabHow we knowReport a problem
- Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the LiverRecruitingNot applicableMassachusetts General HospitalNCT07364474One arm adds it with ipilimumab to liver perfusionHow we knowReport a problem
- Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07405164One continued partner in a belzutifan extensionWritten as NivolumabHow we knowReport a problem
- The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical TrialsRecruitingPhase 4PfizerNCT05203172One continued partner of encorafenib and binimetinibWritten as NivolumabHow we knowReport a problem
- Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)RecruitingPhase 2Mark BernardNCT07770100In every armOne checkpoint option; SBRT is addedWritten as NivolumabHow we knowReport a problem
- Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk MelanomaRecruitingPhase 2University Health Network, TorontoNCT06319196In every armBoth arms take it; relatlimab is addedWritten as NivolumabHow we knowReport a problem
- Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)RecruitingPhase 2Melanoma Institute AustraliaNCT03340129In every armBoth arms take it with ipilimumab; radiosurgery is addedWritten as NivolumabHow we knowReport a problem
- Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE TrialRecruitingPhase 3SWOG Cancer Research NetworkNCT04510597One systemic option in both arms; nephrectomy is addedHow we knowReport a problem
- Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With SurgeryRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04991025In every armStandard with chemotherapy; certolizumab is addedWritten as NivolumabHow we knowReport a problem
- sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)RecruitingPhase 2Rutgers, The State University of New JerseyNCT05332002Optional partner of the tested sFOLFOXIRI scheduleHow we knowReport a problem
- Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-TrialRecruitingNot applicableNiels FristrupNCT03977571Every arm starts with it; deferred nephrectomy is testedHow we knowReport a problem
- A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesRecruitingPhase 2SWOG Cancer Research NetworkNCT04511013In every armBoth arms take it; encorafenib and binimetinib against ipilimumabWritten as NivolumabHow we knowReport a problem
Showing 20 of 112. See all 112 →
Beside a new treatment under test · 581 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with Nivolumab: relatlimab 18 · linrodostat 12 · sitravatinib 10 · bempegaldesleukin 9 · cabiralizumab 8 · poly ICLC 7 · zanzalintinib 7 · BMS-986310 6
- STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic CarcinomaNot yet recruitingPhase 1/2National Cancer Institute (NCI)NCT07902921Partner of new STAR0602Written as NivolumabHow we knowReport a problem
- Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint InhibitorsRecruitingPhase 1Washington University School of MedicineNCT05629546Partner of memory-like NK cells with relatlimabWritten as NivolumabHow we knowReport a problem
- Study to Evaluate VT3989 in Patients With Metastatic Solid TumorsRecruitingPhase 1/2Vivace Therapeutics, IncNCT04665206One partner of new VT3989 with ipilimumabWritten as Nivolumab & IpilimumabHow we knowReport a problem
- A Multicenter Study Evaluating the Efficacy and Safety of Nivolumab and Ipilimumab in Combination With NP-101 Versus Placebo in Refractory Advanced and Metastatic Gastroenteropancreatic Neuroendocrine Carcinomas (GEP-NECs)Not yet recruitingPhase 2/3Novatek PharmaceuticalsNCT07935928In every armGiven with ipilimumab in all arms; new NP-101 is tested against placeboHow we knowReport a problem
- A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).RecruitingPhase 3Bristol-Myers SquibbNCT06646276Partner of new atigotatug in a fixed-dose combinationHow we knowReport a problem
- Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 FailureRecruitingPhase 2CatalYm GmbHNCT07219459Partner of new visugromab with lenvatinibWritten as NivolumabHow we knowReport a problem
- A 2-part Phase 1/2 Open-label Trial on ODM-212RecruitingPhase 1/2Orion Corporation, Orion PharmaNCT07563738Partner of new ODM-212, with ipilimumabHow we knowReport a problem
- Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCCRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT05663710In every armPartner of new 177Lu girentuximab with cabozantinibWritten as NivolumabHow we knowReport a problem
- A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)RecruitingPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT07430202In every armPartner of new DRP-104 and a peptide vaccineWritten as NivolumabHow we knowReport a problem
- Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney CancerRecruitingPhase 2University of Texas Southwestern Medical CenterNCT06601296Maintenance after new IMSA101 and radiotherapyHow we knowReport a problem
- Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyEnrolling by invitationPhase 3ExelixisNCT07620574In every armOne continued partner in an Exelixis extensionWritten as NivolumabHow we knowReport a problem
- Triplet Immunotherapy For Exhausted Cell Targets in Advanced Squamous Cell CarcinomaNot yet recruitingPhase 2Medical College of WisconsinNCT07896811Partner of new vilastobart, with relatlimabHow we knowReport a problem
- Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLCRecruitingPhase 2CatalYm GmbHNCT07246863Partner of new visugromab with docetaxelWritten as NivolumabHow we knowReport a problem
- Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal CancerRecruitingPhase 2Gilead SciencesNCT07527858Partner of new denikitug in one armWritten as NivolumabHow we knowReport a problem
- A LM-302 Combination With Other Anti-Tumor Therapies Phase ll StudyRecruitingPhase 2LaNova Medicines Zhejiang Co., Ltd.NCT05934331One partner of new LM-302Written as NivolumabHow we knowReport a problem
- Axelopran and Nivolumab in PD-1-Refractory Metastatic MelanomaRecruitingPhase 1/2John KirkwoodNCT07631325In every armPartner of new axelopran in melanomaWritten as NivolumabHow we knowReport a problem
- Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2RecruitingPhase 3AstraZenecaNCT07431281Partner of new sonesitatug vedotin; comparator with chemotherapyWritten as NivolumabHow we knowReport a problem
- Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain MetsRecruitingPhase 3InSightecNCT05317858In every armOne checkpoint option; focused ultrasound is testedWritten as NivolumabHow we knowReport a problem
- MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced MelanomaRecruitingPhase 1/2Perspective TherapeuticsNCT05655312Partner of new [212Pb]VMT01Written as NivolumabHow we knowReport a problem
- A Study of TRK-950 in Patients With Advanced Solid TumorsRecruitingPhase 1/2Toray Industries, IncNCT05423262Partner of new TRK-950Written as NivolumabHow we knowReport a problem
Showing 20 of 581. See all 581 →
Beside supportive care · 17 — a supportive treatment or test is studied
- Adjuvant/Neoadjuvant Immunotherapy in Melanoma Based on Serial Plasma ctDNA MonitoringRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT07930182In every armGiven to all; ctDNA testing decides whether ipilimumab is addedWritten as NivolumabHow we knowReport a problem
- Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV MelanomaRecruitingPhase 2NYU Langone HealthNCT05428007In every armEvery arm takes it with ipilimumab; sarilumab is addedWritten as Nivolumab/RelatlimabHow we knowReport a problem
- Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or OlderNot yet recruitingPhase 1University of Southern CaliforniaNCT07838974In every armStandard with ipilimumab; anakinra and tocilizumab are addedWritten as NivolumabHow we knowReport a problem
- Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal CarcinomaRecruitingPhase 4Centre Francois BaclesseNCT07028125Every patient takes it with cabozantinib; digital monitoring is testedHow we knowReport a problem
- Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLCRecruitingPhase 2Second Affiliated Hospital of Nanchang UniversityNCT06554613In every armOne checkpoint option; olanzapine is testedWritten as NivolumabHow we knowReport a problem
- Physical Activity Directly Before Immunotherapy (Nivolumab and Ipilimumab) in MelanomaRecruitingNot applicableUniversitätsklinikum Hamburg-EppendorfNCT07564570Both arms take it with ipilimumab; exercise is testedHow we knowReport a problem
- CD8 PET Imaging in Metastatic Solid TumoursRecruitingPhase 2University Medical Center GroningenNCT06534190In every armStandard treatment beside a CD8 PET tracerWritten as NivolumabHow we knowReport a problem
- Study to Evaluate Impact® as Support to Anti PD1 or Anti PD1 Based Regimen Treatment in Patients With Inoperable Locally Advanced or Metastatic MelanomaRecruitingNot applicableFondazione Melanoma OnlusNCT06880198Every patient takes it; Oral Impact is testedHow we knowReport a problem
- Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II TrialNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07050524One checkpoint option in both arms; omega-3 is addedHow we knowReport a problem
- Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab MonotherapyRecruitingNot applicableHospices Civils de LyonNCT04605146Both groups take it; telemonitoring is testedHow we knowReport a problem
- The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)SuspendedNot applicableNational Cancer Institute (NCI)NCT04866810One immunotherapy option; diet and exercise are testedHow we knowReport a problem
- Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin MalignancyActive, not recruitingPhase 1University of Southern CaliforniaNCT04387084In every armOne checkpoint option; fasting is testedWritten as NivolumabHow we knowReport a problem
- Exercise to Boost Response to Checkpoint Blockade ImmunotherapyActive, not recruitingEarly Phase 1H. Lee Moffitt Cancer Center and Research InstituteNCT05358938One checkpoint option; exercise is testedHow we knowReport a problem
- Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma PatientsActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT06250335In every armPartner with ipilimumab; a prebiotic diet is testedWritten as NivolumabHow we knowReport a problem
- A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell CarcinomaTerminatedNot applicableGustave Roussy, Cancer Campus, Grand ParisNCT05119010Every arm takes it with ipilimumab; ketogenic diet is testedHow we knowReport a problem
- CAcTUS - Circulating Tumour DNA Guided SwitchActive, not recruitingPhase 2The Christie NHS Foundation TrustNCT03808441Both arms switch to it with ipilimumab; ctDNA timing is testedHow we knowReport a problem
- INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell CarcinomaTerminatedNot applicableDuke UniversityNCT03692338Every arm takes it with ipilimumab; exercise is testedHow we knowReport a problem
One option of several · 9 — a test or a strategy chooses among drugs
- Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)RecruitingPhase 1University of California, IrvineNCT05733689In every armOne option in response-adapted therapyWritten as NIVOLUMAB (alone or when added to a regimen above)How we knowReport a problem
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingPhase 2Peking University Shenzhen HospitalNCT06692491One option in organoid-guided therapyWritten as NivolumabHow we knowReport a problem
- CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLCActive, not recruitingPhase 2Candel Therapeutics, Inc.NCT04495153In every armOne standard checkpoint drug continued beside new CAN-2409How we knowReport a problem
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedPhase 1OHSU Knight Cancer InstituteNCT03878524In every armOne of many options in a biopsy-guided trialWritten as NivolumabHow we knowReport a problem
- Brazilian Lung Immunotherapy StudyCompletedPhase 2Hospital Israelita Albert EinsteinNCT05081674One second-line option in Brazilian lung cancer careWritten as NivolumabHow we knowReport a problem
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingPhase 2Fondazione per la Medicina PersonalizzataNCT04591431One tailored option in the ROME trialWritten as NivolumabHow we knowReport a problem
- Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal CancerCompletedPhase 2Vejle HospitalNCT03251612One drug the sensitivity test can chooseHow we knowReport a problem
- An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker AssessmentCompletedPhase 1Bristol-Myers SquibbNCT03335540In every armEvery arm takes it; combinations are matched by biomarkerWritten as NivolumabHow we knowReport a problem
- Biomarker-driven Therapy for MelanomaCompletedNot applicableCharite University, Berlin, GermanyNCT05063058One option in molecular guided therapyHow we knowReport a problem
Given beside what is tested · 1 — usual care or a partner of the new treatment
As the comparator · 38 — what is tested is compared with Nivolumab
- Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsRecruitingPhase 3Boehringer IngelheimNCT07195695One comparator option against zongertinibWritten as NivolumabHow we knowReport a problem
- A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)RecruitingPhase 2Brian RiniNCT07188896The comparator with ipilimumab for fianlimab and cemiplimabWritten as NivolumabHow we knowReport a problem
- Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)RecruitingPhase 2/3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06879145After surgery in the chemotherapy control against SHR-A2102Written as Nivolumab InjectionHow we knowReport a problem
- A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)RecruitingPhase 3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07672223One comparator option against new SYS6010Written as NivolumabHow we knowReport a problem
- A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 3Hoffmann-La RocheNCT07541170One comparator option against divarasibWritten as NivolumabHow we knowReport a problem
- A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)RecruitingPhase 3Regeneron PharmaceuticalsNCT06246916The comparator with relatlimab for new fianlimab and cemiplimabWritten as relatlimab+nivolumabHow we knowReport a problem
- Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With MelanomaRecruitingPhase 1Biocon Biologics UK PLCNCT07476326The reference for biosimilar Bmab1700Written as OpdivoHow we knowReport a problem
- A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)RecruitingPhase 2/3Bristol-Myers SquibbNCT07221149The comparator with chemotherapy for new pumitamigWritten as NivolumabHow we knowReport a problem
- SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaRecruitingPhase 3Immatics US, Inc.NCT06743126One comparator option against new IMA203Written as nivolumab plus relatlimabHow we knowReport a problem
- Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] MelanomaRecruitingPhase 3mAbxience Research S.L.NCT07221734The reference for biosimilar MB11How we knowReport a problem
- A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal CancerNot yet recruitingPhase 2Summit TherapeuticsNCT07877194The comparator with ipilimumab for ivonescimabWritten as Nivolumab combined with IpilimumabHow we knowReport a problem
- Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal CancerRecruitingPhase 2/3PfizerNCT07392892The comparator with chemotherapy for new PF-08634404Written as NivolumabHow we knowReport a problem
- Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ AdenocarcinomaRecruitingPhase 3AkesoNCT07700979The comparator with CAPOX for new cadonilimabWritten as NivolumabHow we knowReport a problem
- A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid TumorsRecruitingPhase 1Shanghai Henlius BiotechNCT07518043The reference for biosimilar HLX18Written as OPDIVO®How we knowReport a problem
- An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUCRecruitingPhase 3AstraZenecaNCT07720284One comparator option against Dato-DXd with rilvegostomigWritten as NivolumabHow we knowReport a problem
- VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]RecruitingPhase 3Replimune, Inc.NCT06264180Partner of new vusolimogene against physician's choiceWritten as NivolumabHow we knowReport a problem
- Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric AdenocarcinomasRecruitingPhase 3Centre Leon BerardNCT06346197The comparator with chemotherapy for new botensilimab and balstilimabWritten as NivolumabHow we knowReport a problem
- A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory MelanomaRecruitingPhase 2/3Linnaeus Therapeutics, Inc.NCT06624644One comparator option against new LNS8801How we knowReport a problem
- IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)RecruitingPhase 3Immunocore LtdNCT06112314Both arms take it; new brenetafusp is addedWritten as NivolumabHow we knowReport a problem
- Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLCRecruitingPhase 2Fudan UniversityNCT07398937The comparator with chemotherapy for serplulimabWritten as Nivolumab + chemotherapyHow we knowReport a problem
Showing 20 of 38. See all 38 →
Observed · 229 — patients on it are followed, or it is given outside a trial
- Lymph Node Metastasis Pattern After Neoadjuvant Chemoimmunotherapy in LAGCNot yet recruitingHainan General HospitalNCT07899775One PD-1 option with SOX in gastric cancerHow we knowReport a problem
- Maintenance Therapy in Metastatic Gastric Cancer: A Multicenter Retrospective Study in ColombiaRecruitingFundación Santa Fe de BogotaNCT07856212One maintenance option in Colombian gastric cancerHow we knowReport a problem
- Development and Analysis of a Stool Bank for Cancer PatientsEnrolling by invitationPersephone BiosciencesNCT04291755One checkpoint option in a stool bankHow we knowReport a problem
- JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint InhibitorsRecruitingGroupe Hospitalier Pitie-SalpetriereNCT04294771One checkpoint option in a heart toxicity databaseHow we knowReport a problem
- Biomarker and Mechanism Study of Systemic Therapy in Unresectable HCCNot yet recruitingShanghai Zhongshan HospitalNCT07786792With ipilimumab in a liver cancer biomarker studyHow we knowReport a problem
- Microbiota in Neoadjuvant Chemoimmunotherapy for NSCLCNot yet recruitingGuangdong Provincial People's HospitalNCT07752589One PD-1 option in a lung cancer microbiota studyHow we knowReport a problem
- Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant AppRecruitingMayo ClinicNCT06675643With ipilimumab in a toxicity app studyHow we knowReport a problem
- Impact of Physical Activity on Immunotherapy-induced Toxicities in Melanoma ManagementRecruitingUniversity Hospital, MontpellierNCT06627595One immunotherapy option in a physical activity studyHow we knowReport a problem
- First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)RecruitingBristol-Myers SquibbNCT07679061First-line use with ipilimumab in liver cancer in JapanWritten as Nivolumab plus ipilimumabHow we knowReport a problem
- ITTACA (Immunotherapy Time Teller for Advanced Lung Cancer)Not yet recruitingLaura LongshawNCT07661251One checkpoint option in a body clock studyHow we knowReport a problem
- A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL)RecruitingOno Pharmaceutical Co., Ltd.NCT07169708Neoadjuvant real-world use with chemotherapy in lung cancerHow we knowReport a problem
- Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)RecruitingGazi UniversityNCT07394062With ipilimumab and chemotherapy in lung cancerWritten as NivolumabHow we knowReport a problem
- TDM for Optimized Outcome in Patients With mRCC.RecruitingNiels FristrupNCT04659343Plasma concentration monitoring with ipilimumab in kidney cancerHow we knowReport a problem
- Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune MicroenvironmentRecruitingFudan UniversityNCT07147101With ipilimumab in a liver cancer cohortWritten as NivolumabHow we knowReport a problem
- Response to Neoadjuvant Treatment in Locally Advanced Thyroid CancerRecruitingFujian Medical UniversityNCT07419932One PD-1 option in neoadjuvant thyroid cancerHow we knowReport a problem
- Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.RecruitingSpanish Oncology Genito-Urinary GroupNCT06724159Adjuvant real-world use in urothelial cancer in SpainHow we knowReport a problem
- Montreal Immune-Related Adverse Events (MIRAE) StudyRecruitingSir Mortimer B. Davis - Jewish General HospitalNCT05139706One checkpoint option in a side effect biobankHow we knowReport a problem
- Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic NeviRecruitingJohn KirkwoodNCT06599619Effects of adjuvant anti-PD-1 on neviWritten as Single agent, adjuvant anti-PD1 therapyHow we knowReport a problem
- Large Granular Lymphocytes in mNSCLC Treated With NivolumabRecruitingNecmettin Erbakan UniversityNCT07363811Lymphocyte marker in lung cancerHow we knowReport a problem
- International Multicentric Study ARON-1RecruitingHospital of MacerataNCT05287464One kidney cancer combination in a global registryHow we knowReport a problem
Showing 20 of 229. See all 229 →
As a tool · 11 — an imaging tracer or a test of drug response
- Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung CancerRecruitingEarly Phase 1Oliver JonasNCT07892300One drug in a microdevice measuring local responseHow we knowReport a problem
- Implantable Microdevice In Primary Brain TumorsRecruitingEarly Phase 1Oliver JonasNCT04135807One drug in a microdevice measuring local responseHow we knowReport a problem
- Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)RecruitingPhase 1Vanderbilt-Ingram Cancer CenterNCT07460765Fluorescently labelled as a tracer in head and neck cancerWritten as Nivo800How we knowReport a problem
- Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)RecruitingEarly Phase 1Eben RosenthalNCT07210632Fluorescently labelled as a tracer in gliomaWritten as NivolumabHow we knowReport a problem
- Drug Screening Using IMD in Bladder CancerEnrolling by invitationEarly Phase 1Brigham and Women's HospitalNCT06204614Microdosed in an implanted drug-screening deviceWritten as NivolumabHow we knowReport a problem
- Drug Screening Using Novel IMD in Renal Cell CarcinomaRecruitingPhase 1Oliver JonasNCT05700461One drug in a microdevice measuring local responseHow we knowReport a problem
- Evaluating PD-1/PD-L1 in Locally Advanced Rectal Cancer by Quantitative Fluorescence Molecular EndoscopyNot yet recruitingPhase 1University Medical Center GroningenNCT06304597Fluorescent tracer in rectal cancer endoscopyWritten as OpdivoHow we knowReport a problem
- Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast CancerTerminatedPhase 1Mayo ClinicNCT03432741Microdosed into tumours to test sensitivityWritten as NivolumabHow we knowReport a problem
- CIVO Intratumoural Microdosing of Anti-Cancer Therapies in AustraliaWithdrawnEarly Phase 1Presage BiosciencesNCT04891718Microdosed into a tumour beside MVC-101Written as NivolumabHow we knowReport a problem
- Intratumoral Microdosing of Motolimod in HNSCCTerminatedEarly Phase 1Presage BiosciencesNCT04272333Microdosed into a tumour beside motolimodWritten as NivolumabHow we knowReport a problem
- Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue SarcomaCompletedPhase 1Presage BiosciencesNCT03056599One drug microinjected to read local responseHow we knowReport a problem
What changed recently
From the registry's own updates since Oct 20, 2026.
Started recruiting2
- bNAbs and Anti-PD-1 in HIVNov 16, 2026NCT07820813
- Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal CancerOct 28, 2026NCT07645118
Results posted4
- Pilot Study of Nivolumab in Pediatric Patients With Hypermutant CancersNov 5, 2026NCT02992964
- Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin LymphomaOct 29, 2026NCT03712202
- Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular CarcinomaOct 28, 2026NCT04658147
- Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative CancersOct 20, 2026NCT04416568
Stopped1
- Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial CarcinomaTerminatedNov 17, 2026NCT04940299
Newly registered4
- First-Line Nivolumab Plus Ipilimumab or Cabozantinib Followed by Second-Line Lenvatinib Plus Everolimus in Metastatic TFE-Rearranged Renal Cell CarcinomaNov 18, 2026NCT07947277
- NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCCNov 5, 2026NCT07919717
- An Exploratory Study of Single-Dose Neoadjuvant Nivolumab Without Surgical Delay in Patients With Resectable HCCOct 28, 2026NCT07902258
- MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLCOct 21, 2026NCT07885709
Codes
What other systems call Nivolumab · ClinicalTrials.gg INT006768
- MeSH (NLM) D000077594NivolumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 31YO63LBSNNIVOLUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1597876Confirmed FDA, Wikidata
- Wikidata Q7041828nivolumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C68814NivolumabOne source FDA
- DrugBank DB09035One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077594 | Nivolumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 31YO63LBSN | NIVOLUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1597876 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7041828 | nivolumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C68814 | Nivolumab | One source FDA |
| DrugBank | DB09035 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.